ABX 10241

Drug Profile

ABX 10241

Alternative Names: ABX-PTH; ABX10241; Human anti-parathyroid hormone monoclonal antibody; human anti-PTH monoclonal antibody

Latest Information Update: 10 Sep 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abgenix
  • Class Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hyperparathyroidism

Most Recent Events

  • 03 Apr 2006 Abgenix has been acquired and merged into Amgen
  • 18 May 2005 ABX-10241 is available for ex-US licensing (http://www.abgenix.com)
  • 11 May 2005 Enrolment into a phase I study is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top